Blinklab Ltd
BB1.AX
Australian Securities Exchange0.65
AUD
+0.01
- -
Blinklab Ltd
BB1.AX
(Australian Securities Exchange)
Recent
price
0.65
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- BlinkLab Ltd is a digital health company focused on smartphone-based neurobehavioral diagnostics and AI-powered analytics. It licenses its intellectual property to commercialize a smartphone application and secure online platform that perform neurometric tests to aid in diagnosing autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), schizophrenia, and related neurodevelopmental conditions; the system records test results on a smartphone and uploads data to BlinkLab’s confidential platform for analysis and reporting. BlinkLab operates primarily in Australia with research and development activities centered in Sydney, and it maintains partnerships and licensing arrangements that support the deployment of its diagnostic tools in clinical and research settings. The company emphasizes longitudinal data capture, remote testing capabilities, and integration with clinical workflows to support early detection and intervention strategies. BlinkLab was founded in 2021 and is headquartered in Sydney, Australia, with commercial activities and potential partnerships extending to global markets through licensing and collaborations. Subsidiaries and parent relationships are structured to enable IP licensing, platform hosting, and data security for healthcare applications. The core offering comprises the BlinkLab Dx product family, including diagnostic adjuncts and neurodevelopmental screening workflows, underpinned by AI and machine learning to enhance accuracy and accessibility. BlinkLab targets pediatric and clinical customers, including healthcare providers, researchers, and partner institutions seeking scalable, smartphone-enabled neurometric evaluations that complement traditional diagnostic pathways. The latest strategic updates reflect expanded licensing partnerships, ongoing product refinements, and prospective clinical collaborations to broaden adoption and support regulatory-compliant deployment in diverse jurisdictions.